Tissue Diagnostics Market by Product (Accessories, Consumables, Instruments), Technology (Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization), Indications, End-User - Global Forecast 2023-2030
The Tissue Diagnostics Market is projected to reach USD 14.02 billion by 2030 from USD 7.71 billion in 2022, at a CAGR of 7.74% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Tissue Diagnostics Market.
- Based on Product, market is studied across Accessories, Consumables, Instruments, and Software. The Consumables is further studied across Antibodies, Kits, Probes, and Reagents. The Instruments is further studied across Scanners, Slide-staining Systems, Tissue Microarrays, and Tissue-processing Systems. The Consumables commanded largest market share of 46.12% in 2022, followed by Instruments.
- Based on Technology, market is studied across Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization, and Special Staining. The Special Staining commanded largest market share of 24.23% in 2022, followed by Immunohistochemistry.
- Based on Indications, market is studied across Breast Cancer, Gastric Cancer, Lymphoma, Non Small Cell Lung Cancer, and Prostate Cancer. The Lymphoma commanded largest market share of 19.42% in 2022, followed by Non Small Cell Lung Cancer.
- Based on End-User, market is studied across Clinical Pathology, Contract Research Organization, Hospitals, Pharmaceutical Organizations, and Research Laboratories. The Clinical Pathology commanded largest market share of 31.91% in 2022, followed by Hospitals.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.68% in 2022, followed by Americas.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Tissue Diagnostics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Tissue Diagnostics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Tissue Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam Plc, Agilent Technologies, Inc., Atlas Antibodies AB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenex Laboratories Inc., BioIVT, LLC, bioMérieux SA, Cardinal Health, Inc., Castle Biosciences, Inc., Cell Signaling Technology, Inc., Diagnostic BioSystems Inc., F. Hoffmann-La Roche Ltd, Leica Biosystems by Danaher Corporation, McKesson Corporation, Merck KGaA, MILESTONE MEDICAL Srl, PathAI, Inc., Pfizer Inc., PROGEN Biotechnik GmbH, QIAGEN N.V., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens Healthineers AG, SLEE medical GmbH, and Thermo Fisher Scientific Inc..
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Tissue Diagnostics Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Tissue Diagnostics Market?
- What is the competitive strategic window for identifying opportunities in the Tissue Diagnostics Market?
- What are the latest technology trends and regulatory frameworks in the Tissue Diagnostics Market?
- What is the market share of the leading vendors in the Tissue Diagnostics Market?
- Which modes and strategic moves are suitable for entering the Tissue Diagnostics Market?
Please Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Tissue Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidence of cancer worldwide
- 5.1.1.2. Growing use of personalized medicine
- 5.1.1.3. Government initiatives to increase awareness regarding effective and early cancer diagnosis
- 5.1.2. Restraints
- 5.1.2.1. High cost involved in tissue diagnosis and reimbursement issues
- 5.1.3. Opportunities
- 5.1.3.1. Inception of digital pathology and automated tissue diagnostics
- 5.1.3.2. Innovative technologies and instruments development in tissue diagnostic field
- 5.1.4. Challenges
- 5.1.4.1. Limitations associated with tissue diagnostics procedures coupled with privacy concerns
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Proliferating use of tissue-processing systems for efficient processing and analyzing diagnosing tissue samples
- 5.2.2. Technology: Adoption of digital pathology technology for the management of digitized histological samples through computer technology
- 5.2.3. Indications: Exponential use of tissue diagnostics in the detection and characterization of numerous cancer types
- 5.2.4. End-User: Significant utilization of tissue diagnostics in clinical pathology laboratories to improve patient care quality
- 5.3. Market Trend Analysis
- 5.3.1. Significant emphasis on securing approvals for tissue diagnostic technologies in the Americas
- 5.3.2. Government initiatives to encourage early detection and screening of chronic diseases in the APAC region
- 5.3.3. Revolutionary advancements in tissue diagnostic technologies in the EMEA region
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Tissue Diagnostics Market, by Product
- 6.1. Introduction
- 6.2. Accessories
- 6.3. Consumables
- 6.4.1. Antibodies
- 6.4.2. Kits
- 6.4.3. Probes
- 6.4.4. Reagents
- 6.4. Instruments
- 6.5.1. Scanners
- 6.5.2. Slide-staining Systems
- 6.5.3. Tissue Microarrays
- 6.5.4. Tissue-processing Systems
- 6.5. Software
- 7. Tissue Diagnostics Market, by Technology
- 7.1. Introduction
- 7.2. Digital Pathology & Workflow
- 7.3. Immunohistochemistry
- 7.4. In Situ Hybridization
- 7.5. Special Staining
- 8. Tissue Diagnostics Market, by Indications
- 8.1. Introduction
- 8.2. Breast Cancer
- 8.3. Gastric Cancer
- 8.4. Lymphoma
- 8.5. Non Small Cell Lung Cancer
- 8.6. Prostate Cancer
- 9. Tissue Diagnostics Market, by End-User
- 9.1. Introduction
- 9.2. Clinical Pathology
- 9.3. Contract Research Organization
- 9.4. Hospitals
- 9.5. Pharmaceutical Organizations
- 9.6. Research Laboratories
- 10. Americas Tissue Diagnostics Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Tissue Diagnostics Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Tissue Diagnostics Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Bio-Techne Buys Lunaphore to Boost Cancer Diagnostics Through Spatial Biology
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
- 13.3.2.2. Roche Expands Collaboration with Janssen to Advance Personalized Healthcare Through Companion Diagnostics
- 13.3.2.3. Guardant Health to Integrate Lunit's Ai-Based Scoring Algorithm for Pd-L1 into its Portfolio to Enhance Cancer Biomarker Detection
- 13.3.2.4. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
- 13.3.3.2. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
- 13.3.4. Investment & Funding
- 13.3.4.1. Ibex Raises USD 55 Million in Series C Funding to Drive Global Adoption of AI for Cancer Diagnosis
- 13.3.4.2. Lunaphore Secures Chf 40 Million to Boost Portfolio of Tissue Diagnostics Solutions
- 13.3.4.3. Microsoft Strikes Partnership with Paige to Advance Cancer Diagnostics and Treatment
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services
- 13.3.5.2. Cytelabs expanding diagnostic services to hospitals and patients across south India
- 13.3.5.3. Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
- 13.3.5.4. Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
- 13.3.5.5. ROCHE tissue diagnostics celebrates marana expansion project
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Abcam Plc
- 14.1.3. Agilent Technologies, Inc.
- 14.1.4. Atlas Antibodies AB
- 14.1.5. Bio-Rad Laboratories, Inc.
- 14.1.6. Bio-Techne Corporation
- 14.1.7. Biogenex Laboratories Inc.
- 14.1.8. BioIVT, LLC
- 14.1.9. bioMérieux SA
- 14.1.10. Cardinal Health, Inc.
- 14.1.11. Castle Biosciences, Inc.
- 14.1.12. Cell Signaling Technology, Inc.
- 14.1.13. Diagnostic BioSystems Inc.
- 14.1.14. F. Hoffmann-La Roche Ltd
- 14.1.15. Leica Biosystems by Danaher Corporation
- 14.1.16. McKesson Corporation
- 14.1.17. Merck KGaA
- 14.1.18. MILESTONE MEDICAL Srl
- 14.1.19. PathAI, Inc.
- 14.1.20. Pfizer Inc.
- 14.1.21. PROGEN Biotechnik GmbH
- 14.1.22. QIAGEN N.V.
- 14.1.23. Quest Diagnostics Incorporated
- 14.1.24. Sekisui Diagnostics, LLC
- 14.1.25. Siemens Healthineers AG
- 14.1.26. SLEE medical GmbH
- 14.1.27. Thermo Fisher Scientific Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook